A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Abroad (travel likely)CompletedPHASE1, PHASE2

Conditions

Carcinoma, Non-Small-Cell Lung

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Birmingham, Alabama, United States
Tucson, Arizona, United States
Loma Linda, California, United States
Sacramento, California, United States
San Francisco, California, United States
Aurora, Colorado, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Lafayette, Indiana, United States
Boston, Massachusetts, United States
St Louis, Missouri, United States
Buffalo, New York, United States
New York, New York, United States
Cincinnati, Ohio, United States
Portland, Oregon, United States
Pittsburgh, Pennsylvania, United States
Charleston, South Carolina, United States
Nashville, Tennessee, United States
Dallas, Texas, United States
Edmonton, Alberta, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Heidelberg, Mannheim, Germany
Bad Berka, Germany
Frankfurt, Germany
Heidelberg, Germany
Lungenklinik, Germany
Ulm, Germany
Seoul, Gangnam-gu, South Korea
Seoul, Seodaemun-gu, South Korea
Barcelona, Spain
Madrid, Spain
Málaga, Spain
Guishan, Taoyuan County, Taiwan
Taichung, Taiwan
Taichung, Taiwan
Tainan, Taiwan
Taipei, Taiwan

Study leads

Victor Moyo, MD
Study Director
Merrimack Pharmaceuticals

View source on ClinicalTrials.gov